Therma Bright Inc. provided an update on its AcuVidTM COVID-19 Rapid Antigen Saliva Test and awaits an official response from the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) review for its COVID-19 rapid antigen test application. In addition to exceeding the minimum results for FDA-EUA review with the initial 63 tests from the Brazilian AcuVidTM Saliva /RT-PCR Test Clinical Study, which was publicly announced in June 2021, the Company continued to recruit individuals in the clinical study to secure additional real-life patient data on its AcuVidTM saliva test. In total, 264 individuals were enrolled in the study with duration of symptoms that ranged from one (1) day to more than 10 days.